Brainstorm Cell Therapeutics Company Profile (NASDAQ:BCLI)

About Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Brainstorm Cell Therapeutics logoBrainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BCLI
  • CUSIP: N/A
  • Web: www.brainstorm-cell.com
Capitalization:
  • Market Cap: $79.89 million
  • Outstanding Shares: 18,842,000
Average Prices:
  • 50 Day Moving Avg: $4.12
  • 200 Day Moving Avg: $4.19
  • 52 Week Range: $2.06 - $5.18
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.59
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.28 per share
  • Price / Book: 15.14
Profitability:
  • EBITDA: ($5,810,000.00)
  • Return on Equity: -76.45%
  • Return on Assets: -59.84%
Debt:
  • Current Ratio: 1.78%
  • Quick Ratio: 10.82%
Misc:
  • Average Volume: 87,254 shs.
  • Beta: 2.28
  • Short Ratio: 5.85
 

Frequently Asked Questions for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

What is Brainstorm Cell Therapeutics' stock symbol?

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) issued its quarterly earnings results on Tuesday, October, 17th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. During the same quarter in the prior year, the company earned ($0.09) EPS. View Brainstorm Cell Therapeutics' Earnings History.

When will Brainstorm Cell Therapeutics make its next earnings announcement?

Brainstorm Cell Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March, 29th 2018. View Earnings Estimates for Brainstorm Cell Therapeutics.

Where is Brainstorm Cell Therapeutics' stock going? Where will Brainstorm Cell Therapeutics' stock price be in 2017?

1 analysts have issued twelve-month target prices for Brainstorm Cell Therapeutics' shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Brainstorm Cell Therapeutics' share price to reach $9.00 in the next year. View Analyst Ratings for Brainstorm Cell Therapeutics.

Who are some of Brainstorm Cell Therapeutics' key competitors?

Who are Brainstorm Cell Therapeutics' key executives?

Brainstorm Cell Therapeutics' management team includes the folowing people:

  • Irit Arbel, Independent Chairman of the Board
  • Chaim Lebovits, President, Chief Executive Officer
  • Alla Patlis, Interim Chief Financial Officer
  • Ralph Kern, Chief Operating Officer and Chief Medical Officer
  • Uri Yablonka, Executive Vice President, Chief Business Officer, Director
  • Chen Schor CPA, Director
  • June S. Almenoff M.D. Ph.D., Independent Director
  • Arturo O. Araya, Independent Director
  • Mordechai Friedman, Independent Director
  • Alon Pinkas, Independent Director

How do I buy Brainstorm Cell Therapeutics stock?

Shares of Brainstorm Cell Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Brainstorm Cell Therapeutics' stock price today?

One share of Brainstorm Cell Therapeutics stock can currently be purchased for approximately $4.24.


MarketBeat Community Rating for Brainstorm Cell Therapeutics (NASDAQ BCLI)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  98 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  145
MarketBeat's community ratings are surveys of what our community members think about Brainstorm Cell Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Brainstorm Cell Therapeutics (NASDAQ:BCLI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.00 (112.26% upside)
Consensus Price Target History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Price Target History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Analysts' Ratings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017Maxim GroupSet Price TargetBuy$9.00N/AView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Earnings by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Earnings History by Quarter for Brainstorm Cell Therapeutics (NASDAQ BCLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2018        
10/17/2017Q3 2017($0.16)($0.13)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.10)($0.06)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.30)($0.10)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.07)($0.03)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.11)($0.09)ViewN/AView Earnings Details
8/11/2016Q2($0.18)($0.05)ViewN/AView Earnings Details
5/10/2016Q116($0.25)($0.10)ViewN/AView Earnings Details
3/10/2016Q415($0.15)($0.07)ViewN/AView Earnings Details
11/17/2015Q3($0.14)($0.14)ViewN/AView Earnings Details
8/13/2015Q215($0.13)($0.12)ViewListenView Earnings Details
5/14/2015Q115($0.14)($0.12)ViewListenView Earnings Details
3/26/2015Q414($0.18)($0.18)ViewN/AView Earnings Details
11/13/2014($0.12)($0.16)ViewN/AView Earnings Details
11/13/2014Q3 14($0.12)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.10)($0.10)($0.10)
Q3 20171($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Insider Ownership Percentage: 24.70%
Institutional Ownership Percentage: 12.69%
Insider Trades by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Institutional Ownership by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Insider Trades by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2017Irit ArbelDirectorBuy2,500$4.26$10,650.00View SEC Filing  
8/23/2017Uri YablonkaEVPBuy2,000$3.98$7,960.00View SEC Filing  
12/16/2015Robert G L ShorrDirectorSell10,800$2.71$29,268.00View SEC Filing  
12/15/2015Malcolm S. TaubDirectorSell41,742$2.60$108,529.20View SEC Filing  
12/11/2015Malcolm S. TaubDirectorSell13,480$2.73$36,800.40View SEC Filing  
10/1/2015International Holdings Ltd AccMajor ShareholderBuy2,000$2.58$5,160.00View SEC Filing  
9/30/2015International Holdings Ltd AccMajor ShareholderBuy9,200$2.34$21,528.00View SEC Filing  
8/20/2015Yoram BibringCFOBuy8,500$3.04$25,840.00View SEC Filing  
8/17/2015Yoram BibringCFOBuy41,500$2.92$121,180.00View SEC Filing  
10/10/2014International Holdings Ltd AccMajor ShareholderBuy8,600$4.06$34,916.00View SEC Filing  
10/1/2014International Holdings Ltd AccMajor ShareholderBuy6,700$4.14$27,738.00View SEC Filing  
9/22/2014International Holdings Ltd AccMajor ShareholderBuy11,000$4.17$45,870.00View SEC Filing  
9/15/2014Anthony S FiorinoCEOBuy18,000$0.28$5,040.00View SEC Filing  
6/16/2014International Holdings Ltd AccMajor ShareholderBuy130,000$0.29$37,700.00View SEC Filing  
6/13/2014International Holdings Ltd AccMajor ShareholderBuy150,000$0.35$52,500.00View SEC Filing  
4/28/2014International Holdings Ltd AccMajor ShareholderBuy939,600$0.30$281,880.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Latest Headlines for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Source:
Loading headlines, please wait.

Social

Chart

Brainstorm Cell Therapeutics (BCLI) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.